Adrenocortical Carcinoma
Treatment Market: Regional Dynamics
Regional segmentation of the
global Adrenocortical
Carcinoma Treatment Market by Coherent Market Insights comprises North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North
America is expected to hold a dominant position in the global adrenocortical
carcinoma treatment market over the forecast period, owing to rise in
prevalence of the disease and presence of key players that are focusing on
developing novel products, followed by Europe, the next dominating
adrenocortical carcinoma treatment market. According to the National Institutes
of Health Office of Rare Diseases Research, the incidence rate of adrenal
cancer is about 600 new cases per year in the U.S. Moreover, organizations such
as the University of Michigan Rogel Cancer Center are involved in stem cell
research, to advance treatment in adrenal cancer.
Latin America is expected to gain
significant traction in the forecast period, owing to higher incidence rate of
the condition in Brazil. According to the survey ACC C.U.R.E. Organization,
adrenal cancer in Brazil is 15 times more prevalent than any other countries in
the world, attributed to high prevalence of mutation of a single gene TP53.
Also, according to the Endocrine Society, 2014, the incidence during childhood
is 2.9 to 4.2 per million per year in Brazil compared with an estimated
incidence of 0.2 to 0.3 per million children per year worldwide. Moreover, the
University of Michigan has been collaborating with the Adrenal Cancer Group in
Sao Paulo to bring about the advancements in adrenal cancer research, thus
providing better clinical outcomes for patients in the region.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1551
Adrenocortical carcinoma is a
rare cancer affecting the outer layer of the adrenal glands, which are
responsible for producing certain hormones and maintaining optimum blood
pressure levels. Adrenocortical carcinoma is relatively frequent in children
compared to other cancers, although the cancer may also affect adults. The most
common symptoms of adrenocortical carcinoma include abdominal pain,
hypertension, weight gain, and frequent urination, which are mainly caused due
to tumors causing excess secretion of hormones from the adrenal glands. Mitotane
is the only drug approved by the U.S. Food and Drug Administration (FDA) and
European Medicine Executive Agency (EMEA) for treatment of metastatic
adrenocortical carcinoma. According to the study by HealthLine Media, 2017,
about 5-10% of the adrenal tumors are malignant. Diagnosis of adrenocortical
carcinoma is based on urine tests, dexamethasone suppression test for detecting
abnormal levels of cortisol, which is the hormone released by the adrenal
glands. Also, a wide number of imaging devices are used for diagnoses of the
disease, which includes CT scan, MRI, PET scan, and MIBG Scan, thus aiding for
faster disease identification that aids the doctors to decide for further
treatments.
Adrenocortical Carcinoma Treatment
Market: Market Dynamics
Increasing incidence of
adrenocortical carcinoma associated with genetic disorders is a major factor
augmenting growth of the adrenocortical carcinoma treatment market. According
to the Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidence
of adrenocortical carcinoma ranges between 40-50 years, where women are 55–60%
more likely to get affected with a ratio of ratio 1.5:1. The study also states
that adrenocortical carcinoma is a rare and highly aggressive malignancy with
an annual incidence of 0.05–0.2% or 1-2 cases per million population globally.
Also, inherited disorders such as Li-Fraumeni syndrome (LFS),
Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with
increasing incidence of adrenocortical carcinoma. According to the survey by
Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3%
to 10% of malignancies in LFS and over 5-15% of malignancies in BWS. Moreover,
according to the study by Medscape, 2017, adrenocortical carcinoma accounted
for 0.02-0.2% of all cancer-related deaths, globally.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/adrenocortical-carcinoma-treatment-market-1551
Moreover, number of clinical
trials are increasing for different chemotherapeutics by various organizations
and manufacturers. For instance, Millendo Therapeutics, Inc., initiated the
Phase 1 trial for ATR-101 in 2013 to treat adrenocortical carcinoma. Also, the
National Cancer Institute initiated a Phase 2 trial for Phase II trial of
Cisplatin and sodium thiosulfate for surgical resection and Heated
Intraperitoneal Peritoneal Chemotherapy (HIPEC) for adrenocortical carcinoma.
Also, in March 2018, the University of Colorado Anschutz Medical Campus
presented new models to identify genetic targets and test promising treatments
in adrenocortical carcinoma at the ENDO Conference, thus exploring new
therapeutic options for the patients.
Adrenocortical Carcinoma Treatment
Market: Competitive Analysis
Manufactures are focused on
launching novel therapeutic products for treatment of these rare diseases, thus
accelerating market growth. For instance, in 2017, the FDA approved
immunotherapy drug Keytruda (Pembrolizumab), the first anti-PD-1 (programmed
death receptor-1) therapy, developed by Merck & Co., indicated for advanced
adrenocortical carcinoma.
Key players operating in the
global adrenocortical carcinoma treatment market include ArQule, Inc., EnGeneIC
Ltd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and Orphagen
Pharmaceuticals, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1551
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to emerging market
trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment